-
Mashup Score: 22Optimizing Treatment in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study Analysis - Alicia Morgans - 13 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Elena Castro, MD, PhD, Hospital…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 15Landscape of Approved and Upcoming PSMA Imaging Agents "Presentation" - Amir Iravani - 13 day(s) ago
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar specificity and modest sensitivity for lymph node detection. He questions the need for multiple trials per agent, emphasizing quality interpretation through standardized reporting matters more than which tracer…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Landscape of approved and upcoming PSMA imaging agents. @DrAIravani @fredhutch presents at the 2025 UCSF-UCLA #PSMAConference comparing FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. #WatchNow > https://t.co/QsYm3KbLGV https://t.co/6NrlhDpGKG
-
-
Mashup Score: 59
Zachary Klaassen speaks with Andrea Apolo about co-chairing the inaugural GU Early Thought Leaders Conference. Dr. Apolo explains why such career-focused events are vital, noting that the transition from fellowship to independent faculty represents one of the most challenging career phases. Unlike traditional scientific meetings, this conference focused on personal journeys, practical career…
Source: www.urotoday.comCategories: General Medicine NewsTweet-
Had so much fun (see interview https://t.co/j1cfke6UQd ) at the inaugural GU Early Thought Leaders 2025 Conference with @zklaassen where we met many future #GUOncology leaders! @PCFnews @urotoday with outstanding faculty @ERPlimackMD @montypal @ArjunBalarMD @AlanBryce9 @tbivala1 https://t.co/YO0q0fOKkA https://t.co/E8DZigvdex
-
-
Mashup Score: 58
Zachary Klaassen speaks with Andrea Apolo about co-chairing the inaugural GU Early Thought Leaders Conference. Dr. Apolo explains why such career-focused events are vital, noting that the transition from fellowship to independent faculty represents one of the most challenging career phases. Unlike traditional scientific meetings, this conference focused on personal journeys, practical career…
Source: www.urotoday.comCategories: General Medicine NewsTweet-
Had so much fun (see interview https://t.co/j1cfke6UQd ) at the inaugural GU Early Thought Leaders 2025 Conference with @zklaassen where we met many future #GUOncology leaders! @PCFnews @urotoday with outstanding faculty @ERPlimackMD @montypal @ArjunBalarMD @AlanBryce9 @tbivala1 https://t.co/YO0q0fOKkA https://t.co/E8DZigvdex
-
-
Mashup Score: 6The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer - Matthew Abramowitz - 15 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew Abramowitz, MD, Associate Professor, Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Rana McKay, MD , Medical Oncologist, Associate…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
The use of radioligand treatments in metastatic castration-resistant #ProstateCancer. Matthew Abramowitz, MD @SylvesterCancer joins @DrRanaMcKay @UCSanDiego to discuss as part of this Independent Medical Education Initiative on UroToday > https://t.co/X84or9D8N4 @BayerPharma https://t.co/bFzTwblrXZ
-
-
Mashup Score: 29Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate Cancer - Alan Bryce - 16 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alan Bryce, MD, Chief Clinical Officer, City of Hope Cancer Center Pheonix, Phoenix, Arizona Elena Castro, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain Related Content: An Overview in…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Real-world evidence informs clinical decision-making in metastatic castration-resistant #ProstateCancer. @AlanBryce9 @cityofhope joins @Ecastromarcos in this discussion as part of an Independent Medical Education Initiative supported by @BayerPharma > https://t.co/W3eCflNlhO https://t.co/wivvWqyWuf
-
-
Mashup Score: 1Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor - 17 day(s) ago
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A. Oliver Sartor, MD, Professor of Medicine, Urology, and Radiology, Director Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Rana McKay, MD , Medical Oncologist, Associate Professor of…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Case-based discussion on navigating the evolving landscape of castrate-resistant #ProstateCancer management. Oliver Sartor, MD @MayoClinic joins @DrRanaMcKay @UCSanDiego as part of an independent medical education initiative on UroToday > https://t.co/ygi8XDjAQC @BayerPharma https://t.co/OZG83QZgbB
-
-
Mashup Score: 5ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions - Nimira Alimohamed - 17 day(s) ago
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current evidence establishes ctDNA detection as strongly prognostic at multiple timepoints, with detectable ctDNA before neoadjuvant therapy, after neoadjuvant therapy, or post-surgery consistently indicating poor outcomes. She…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
ctDNA as a prognostic biomarker in #BladderCancer treatment decisions. @Nimira_A @UCalgary sits down with @UroDocAsh @MDAndersonNews to discuss the evolution of ctDNA in muscle-invasive bladder cancer management. #WatchNow > https://t.co/KmX7W8mjyI https://t.co/zuOsjnxL8U
-
-
Mashup Score: 46Avelumab’s Survival Impact in Diabetic vs Non-Diabetic Bladder Cancer Patients - Shilpa Gupta - 17 day(s) ago
Ashish Kamat speaks with Shilpa Gupta about the JAVELIN trial and its impact on bladder cancer treatment. Dr. Gupta discusses how this study established avelumab maintenance therapy following platinum-based chemotherapy as a standard of care, improving both overall and progression-free survival. She highlights an abstract examining outcomes in diabetic patients, which shows maintenance avelumab…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Avelumab’s survival impact in diabetic vs non-diabetic #BladderCancer patients. @shilpaonc @ClevelandClinic sits down with @UroDocAsh @MDAndersonNews to discuss the #JAVELIN trial and its impact on bladder cancer treatment. #WatchNow on UroToday > https://t.co/8DNkkeHPuw https://t.co/bkMUChlLve
-
-
Mashup Score: 3
Peyronie’s Disease, Ventral Peyronie’s Disease, Rigicon Inflatable Penile Prosthesis, Penile Prosthesis, Plaque Incision and Grafting with Collagen Fleece, (PICS-Technique, penile curvature after peyronies disease treatment, Rigicon three-piece inflatable penile implant.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
First worldwide correction of ventral #peyronie's disease utilizing rigicon inflatable penile prosthesis combined with plaque incision & grafting with collagen fleece (PICS-Technique) for residual curvature. #AuthorCommentary on UroToday > https://t.co/vkQs6pusT2
-
Optimizing treatment in metastatic hormone-sensitive #ProstateCancer: a case study analysis. @CaPsurvivorship @DanaFarber joins @Ecastromarcos in discussing the State of the Art of prostate cancer in 2024. #WatchNow on UroToday > https://t.co/KJqkw78cMy @BayerPharma https://t.co/xDq72orRs4